Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide

Journal of Neuro-Oncology

Volumn 122, Issue 2, 2015, Pages 273-281

  Goldwirt, Lauriane ^a   Beccaria, Kevin ^b   Carpentier, Alexandre ^b   Idbaih, Ahmed ^b,d   Schmitt, Charlotte ^d   Levasseur, Camille ^d   Labussiere, Marianne ^d   Milane, Aline ^e   Farinotti, Robert ^a   Fernandez, Christine ^a,c  

^a EA4123   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Brain distribution; Glioblastoma; Irinotecan; SN 38; Temozolomide; Tumor distribution

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; DRUG EFFECTS; HUMAN; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BEVACIZUMAB; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TISSUE DISTRIBUTION;

EID: 84925873338     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1717-1     Document Type: Article

References (46)

1. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJF (2004) Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 45(3):143–163
2. Steiner H-H, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C (2004) Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 66(1):129–138
3. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. PNAS 86(2):695–698
4. Jetté L, Murphy GF, Leclerc J-M, BÈliveau R (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50(10):1701–1709
5. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97(11):2517–2524
6. Terasaki T, K-i Hosoya (1999) The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 36(2–3):195–209
7. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62. doi:10.1126/science.1104819
8. Calatozzolo C, Pollo B, Botturi A, Dinapoli L, Carosi M, Salmaggi A, Maschio M (2012) Multidrug resistance proteins expression in glioma patients with epilepsy. J Neurooncol 110(1):129–135. doi:10.1007/s11060-012-0946-9
9. Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, Moumdjian R, Berthelet F, Beliveau R (2001) Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 93(1):62–66
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann Jr, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
11. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2010) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. doi:10.1200/jco.2010.30.2729
12. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722
13. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708
14. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51(16):4187–4191
15. Satoh T, Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38(1):257–288. doi:10.1146/annurev.pharmtox.38.1.257
16. Iyer L, Ramírez J, Shepard D, Bingham C, Hossfeld D-K, Ratain M, Mayer U (2002) Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49(4):336–341
17. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20(2):163–175
18. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM (1998) Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 41(6):464–468. doi:10.1007/s002800050768
19. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516
20. Prados MD, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American brain tumor consortium study. Neuro-Oncology 8(2):189–193. doi:10.1215/15228517-2005-010
21. Baumann BC, Dorsey JF, Benci JL, Joh DY, Kao GD (2012) Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme. J Vis Exp 67:e4089. doi:10.3791/4089
22. Brehar FM, Ciurea AV, Chivu M, Zarnescu O, Radulescu R, Dragu D (2008) The development of xenograft glioblastoma implants in nude mice brain. J Med Life 1(3):275–286
23. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, Kung AL, Mulligan RC, Carter BS (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58(2):365–372
24. Goldwirt L, Zahr N, Farinotti R, Fernandez C (2013) Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. Biomed Chromatogr 27(7):889–893. doi:10.1002/bmc.2877
25. Goldwirt L, Lemaitre F, Zahr N, Farinotti R, Fernandez C (2012) A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. J Pharm Biomed Anal 66:325–333. doi:10.1016/j.jpba.2012.04.003
26. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303–309. doi:10.1007/bf01062139
27. Maity A, Pore N, Lee J, Solomon D, Rourke DM (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3-kinase and distinct from that induced by hypoxia. Cancer Res 60(20):5879–5886
28. Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T (2007) VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360(3):553–559
29. Chan ASY, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, Chung LP (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22(7):816–826
30. Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77(2):362–372
31. Weindel K, Moringlane JR, Marm D, Weich HA (1994) Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery 35(3):439–449
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844
33. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J, Winkler F (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17(19):6192–6205. doi:10.1158/1078-0432.ccr-10-1868
34. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12):1383–1392
35. Gerber H-P, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671–680
36. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WPJ (2008) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 7(1):71–78. doi:10.1158/1535-7163.mct-07-0552
37. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563
38. EMEA (2005) Bevacizumab European public assessment report—Scientific Discussion
39. Goldwirt L, Beccaria K, Carpentier A, Farinotti R, Fernandez C (2014) Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol 74(1):185–193
40. Kemper EM, Leenders W, Küsters B, Lyons S, Buckle T, Heerschap A, Boogerd W, Beijnen JH, van Tellingen O (2006) Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 42(18):3294–3303. doi:10.1016/j.ejca.2006.07.013
41. Matsumoto T, Tani E, Kaba K, Shindo H, Miyaji K (1991) Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74(3):460–466. doi:10.3171/jns.1991.74.3.0460
42. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20(1):175–181. doi:10.1093/annonc/mdn548
43. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74. doi:10.1016/j.ctrv.2010.05.001
44. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB (2012) Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 106(1):111–119. doi:10.1007/s11060-011-0638-x
45. Chamberlain MC (2011) Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5:117–129. doi:10.4137/CMO.S7232
46. Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O (2013) Abcc4 together with Abcb1 and Abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res 19(8):2084–2095. doi:10.1158/1078-0432.ccr-12-3105